TriSalus - שולי רווח נקי TLSI

לוגו גרפי של TriSalus Life Sciences, Inc. (TLSI)

TriSalus Life Sciences is highly valued by oncologists for the synergy between immunotherapy and delivery systems. The company's net margin ratio reflects market dynamics, where the parameter value reaches -56.60. Success is based on the unique PEDD technology for deep penetration into solid tumors. Business stability is ensured by its own R&D and manufacturing complex in the US, which integrates innovative devices with pharmaceuticals.

TriSalus Life Sciences (TLSI) - שולי מכירות של החברה מ-21.02.2024 עד 19.11.2026

TLSI (TriSalus Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

הערכת שווי פונדמנטלית:trisaluslifesci.com, TLSI
סחורת הדגל של TriSalus Life Sciences Inc

The delivery efficiency of targeted drug delivery systems and specialized catheters is reflected in the net profit margin trend, which demonstrates the profit share of every dollar of revenue. This indicator measures the ability of TriSalus Life Sciences (TLSI) to convert operating cash flow into bottom-line income, allowing investors to assess the actual profitability of the business and the sustainability of cost management while scaling immunotherapy.